Fig. 3: BLZF1 is a novel KIT binding partner, which is indispensable for tethering MT-KIT in the Golgi complex.

A Western botting was performed using antibodies against ten Golgi-related proteins in small cell lung carcinoma (SCLC), leukemia, CC, and GIST cell lines expressing WT-KIT or MT-KIT. B Immunoprecipitation analysis was performed in GIST cells using a KIT antibody and binding between KIT and Golgi-related proteins was evaluated by western blotting. C, D Confocal microscopic analysis of GM130, BLZF1, and KIT in GIST cells with or without BLZF1 shRNA treatment. E Western blotting analysis of KIT and BLZF1 in GIST cells with or without BLZF1 shRNA treatment. F A proliferation assay was performed in GIST cells with or without BLZF1 shRNA treatment. Cell growth was measured by MTT analysis 72āh after BLZF1 shRNA treatment. Error bars in F represents the SD of the mean of three independent experiments. One-way ANOVA with a post-hoc test was performed to compare multiple means (*pā<ā0.05, **pā<ā0.01, ***pā<ā0.001).